

Clinical and Translational Toxicology Specialty Section

ANNUAL REPORT: 2025–2026

May 1, 2025 to April 30, 2026

I. Officers:

<u>2025–2026</u>	<u>2026–2027</u>
President: James Dear Vice President: Mitchell McGill Vice President Elect: Renee Bergeron Past President, Councilor: Deidre Dalmas Wilk Secretary-Treasurer: Emma Bowers Councilor: Anup Ramachandran Councilor: Joanna Woo Postdoctoral Representative: Marcus Garcia Graduate Student Representative: Chenghui Jiang	President: Mitchell McGill Vice President: Renee Bergeron Vice President-Elect: Anup Ramachandran Secretary-Treasurer: Deidre Dalmas Wilk Past President, Councilor: James Dear Councilor: Judith Zelikoff Councilor: Joanna Woo Postdoctoral Representative: Chander Negi Graduate Student Representative: Chenghui Jiang

Committees:

Awards Committee

II. 2026 Membership total: 128

III. Key Outcomes and Accomplishments in 2025–2026:

The Clinical and Translational Toxicology Specialty Section accomplished the following activities throughout the year.

- In-person meeting/mixer
- Endorsed session(s) at the Annual Meeting
- Mentoring/career development events
- Trainee awards conferred
- Scientist investigator awards conferred
- Newsletter(s)
- Webinars
- Business meeting (communicated operations/finances to members)

IV. Collaborative Partnerships with Other SOT Organizations:

The Clinical and Translational Toxicology Specialty Section collaborated with the following organizations within SOT.

V. Communication Methods:

The Clinical and Translational Toxicology Specialty Section stayed in contact with its members throughout the year through the following mechanisms.

- Emails through SOT Headquarters
- Specialty Section website

- Newsletter(s)
- Through Graduate Student/Postdoc Representatives

VI. Promotion of Inclusivity

The Clinical and Translational Toxicology Specialty Section maintained an inclusive organization through the following activities.

- Nominate a diverse slate of candidates for elections
- Solicit equitable input from all executive committee leaders
- Utilize virtual meetings for convening Specialty Section leadership
- Utilize standardized rubrics for judging awards/posters
- Include inclusive descriptions of Awards
- Prioritize diversity in selection of speakers/panelists
- Highlight trainee research
- Solicit member feedback for development of Specialty Section activities (such as webinar topics)
- Provide volunteer activities for the membership to be engaged
- Use multiple approaches to communicate with membership

VII. Mentoring and Career Development Activities:

The Clinical and Translational Toxicology Specialty Section hosted the following mentoring activities throughout the year for its membership.

- Mentor-mentee program within the Specialty Section
- Networking luncheon/reception

VIII. Awards Given:

Trainee	6
Early Career	0
Mid Career	0
Late Career	1

IX. Key Outcomes and Improvements:

- A. We continued to work to improve the format and presentation of our annual meeting/mixer. This year was well organized thanks to greater membership engagement and the tireless efforts of Deidre and other members of the section leadership.
- B. During the annual SOT meeting in March, we also hosted our 2nd annual CTTSS mentoring event, ironing out the bugs from a first year doing this event in 2025.

X. Strategic Plan:

The Clinical and Translational Toxicology Specialty Section supported the following SOT Strategic Priorities.

- Proactively pursue impactful scientific content
- Effectively communicate scientific advances
- Foster connectivity across scientific disciplines
- Develop a talent pool of toxicologists for the future

XI. Scientific Topics of Interest:

The Clinical and Translational Toxicology Specialty Section is interested in seeing the following topic areas developed into sessions at future SOT Annual Meetings.

- Translational application of NAMs and human-relevant models to connect mechanistic toxicology findings with clinically meaningful endpoints, human risk assessment, and regulatory decision-making.
- AI, machine learning, and computational toxicology as translational tools to integrate experimental, mechanistic, clinical, and real-world data for improved human toxicity prediction and decision support.
- Fit-for-purpose validation and qualification of emerging translational methods, with emphasis on context of use, biological relevance, reproducibility, uncertainty, and clinical or public health applicability.
- Building regulatory confidence in translational toxicology approaches, including case studies that demonstrate how NAMs, computational models, and integrated evidence streams can inform regulatory and clinical decisions.

XII. Feedback to the Society:

- A. What is the one thing the Society should be doing that it currently does not do (or does not do effectively) that would be of importance/benefit to the members of the Specialty Section?

An up-to-date, SOT-wide webinar calendar that Section leaders can view when trying to schedule their own webinars and ability to hold dates would be helpful.

- B. What is the one thing the Society is currently doing that impacts the Specialty Section that should be changed (e.g., stopped, modified, etc.)?

No longer providing financial support for our face-to-face annual meetings/mixers and simultaneously not allowing specialty sections to meet off-site instead of at the conference center. Costs for these luncheons and dinners have increased precipitously, while Society support has decreased. It would be wonderful if the SOT could provide more financial investment or assistance to specialty sections as in earlier years, allow specialty sections to meet off-site at less expensive venues, and/or negotiate lower food and equipment rental prices with conference centers. The financials are a struggle these days. Modify the SOT rule that would allow the Specialty Section President to appoint another member of the Specialty Section executive committee to attend events the President is invited to if they cannot attend (e.g., Presidents Reception).